LLY

747.7

-1.07%↓

JNJ

148.51

-3.47%↓

UNH

310.52

-17.94%↓

ABBV

187.96

-1.03%↓

ABT

129.08

-2.23%↓

LLY

747.7

-1.07%↓

JNJ

148.51

-3.47%↓

UNH

310.52

-17.94%↓

ABBV

187.96

-1.03%↓

ABT

129.08

-2.23%↓

LLY

747.7

-1.07%↓

JNJ

148.51

-3.47%↓

UNH

310.52

-17.94%↓

ABBV

187.96

-1.03%↓

ABT

129.08

-2.23%↓

LLY

747.7

-1.07%↓

JNJ

148.51

-3.47%↓

UNH

310.52

-17.94%↓

ABBV

187.96

-1.03%↓

ABT

129.08

-2.23%↓

LLY

747.7

-1.07%↓

JNJ

148.51

-3.47%↓

UNH

310.52

-17.94%↓

ABBV

187.96

-1.03%↓

ABT

129.08

-2.23%↓

Search

Erasca Inc

Uždarymo kaina

1.36 -1.45

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

1.32

Max

1.39

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-1M

-32M

Pelnas, tenkantis vienai akcijai

-0.11

Darbuotojai

103

EBITDA

1.5M

-35M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+259.71% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-05-13

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

35M

448M

Ankstesnė atidarymo kaina

2.81

Ankstesnė uždarymo kaina

1.36

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bearish Evidence

Erasca Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-05-12 22:34; UTC

Įsigijimai, susijungimai, perėmimai

Ampol to Sell Retail Electricity Businesses in Australia, New Zealand

2025-05-12 23:48; UTC

Rinkos pokalbiai

Gold Edges Higher on Possible Technical Recovery -- Market Talk

2025-05-12 23:46; UTC

Rinkos pokalbiai

Nikkei Likely to Rise on Hopes for Improving U.S.-China Trade Relations -- Market Talk

2025-05-12 23:34; UTC

Rinkos pokalbiai

Trade Deal Lowers US Recession Risks to 35% -- Market Talk

2025-05-12 23:21; UTC

Rinkos pokalbiai

US-China Trade Deal Still Risks Stagflation; Supply Chain Disruption -- Market Talk

2025-05-12 22:54; UTC

Rinkos pokalbiai

Australian Treasurer Warns Uncertainty Will Still Dominate Markets -- Market Talk

2025-05-12 22:43; UTC

Uždarbis

Telefonica Brasil 1Q EPS BRL0.65 >VIV

2025-05-12 22:14; UTC

Svarbiausios naujienos

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- 2nd Update

2025-05-12 22:08; UTC

Įsigijimai, susijungimai, perėmimai

Ampol Expects Replacement-Cost Ebitda Uplift by Run Rate at End-2025 of Around A$30 Million/Year

2025-05-12 22:08; UTC

Įsigijimai, susijungimai, perėmimai

Ampol Expects Pretax Proceeds of Around A$65 Million From Transactions

2025-05-12 22:07; UTC

Įsigijimai, susijungimai, perėmimai

Ampol to Sell Australia Retail Electricity Business for Nominal Sum

2025-05-12 22:07; UTC

Įsigijimai, susijungimai, perėmimai

Ampol to Sell Australia Retail Electricity Business to AGL

2025-05-12 22:06; UTC

Įsigijimai, susijungimai, perėmimai

Meridian to Take on Flick, Z Energy Branded Electricity Customers

2025-05-12 22:06; UTC

Įsigijimai, susijungimai, perėmimai

Meridian Energy to Buy Business From Ampol for NZ$70 Million

2025-05-12 22:05; UTC

Įsigijimai, susijungimai, perėmimai

Ampol to Sell New Zealand Electricity Retailing Businesses to Meridian Energy

2025-05-12 22:04; UTC

Įsigijimai, susijungimai, perėmimai

Ampol to Sell Retail Electricity Businesses in Australia, New Zealand

2025-05-12 21:15; UTC

Svarbiausios naujienos

Republican Tax Plan Boosts SALT Deduction, Ends Green-Energy Breaks -- 2nd update -- WSJ

2025-05-12 21:01; UTC

Uždarbis

Constellation Software 1Q Rev $2.65B >CSU.T

2025-05-12 21:01; UTC

Uždarbis

Constellation Software 1Q Net $115M >CSU.T

2025-05-12 21:01; UTC

Uždarbis

Constellation Software 1Q EPS $5.44 >CSU.T

2025-05-12 20:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2025-05-12 20:50; UTC

Rinkos pokalbiai
Uždarbis

Basic Materials Roundup: Market Talk

2025-05-12 20:44; UTC

Svarbiausios naujienos

Trade Thaw Sparks Stock Rally, Leaves Wall Street Cautious -- WSJ

2025-05-12 20:31; UTC

Svarbiausios naujienos

How to Think About the Stock Market When Earnings Guidance Becomes Meaningless -- Heard on the Street -- UPDATED -- WSJ

2025-05-12 20:24; UTC

Uždarbis

Energy Vault Holdings: Encouraging News on China/U.S. Tariff Pause, Pending Final Positive Resolution and Timing >NRGV

2025-05-12 20:24; UTC

Uždarbis

Energy Vault Holdings: No Change to Current Guidance, With Potential Rev Upside on Accelerated U.S. Battery Deliveries in 2025 >NRGV

2025-05-12 20:24; UTC

Svarbiausios naujienos

Republican Tax Plan Boosts SALT Deduction, Ends Green-Energy Breaks -- WSJ

2025-05-12 20:22; UTC

Įsigijimai, susijungimai, perėmimai

Spirit AeroSystems Holdings: IRS Rules That Sale to Boeing Will Qualify as a Reorganization Under Section 368(a)(1)(B)

2025-05-12 20:15; UTC

Uždarbis

Rigetti Computing Reports Earnings. How the Company Takes a Different Approach to Quantum. -- Barrons.com

2025-05-12 20:10; UTC

Uždarbis

Blink Charging 1Q Rev $20.8M >BLNK

Akcijų palyginimas

Kainos pokytis

Erasca Inc Prognozė

Kainos tikslas

By TipRanks

259.71% į viršų

12 mėnesių prognozė

Vidutinis 5 USD  259.71%

Aukščiausias 6 USD

Žemiausias 4 USD

Remiantis 5 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Erasca Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

5 ratings

5

Pirkti

0

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

1.39 / 1.44Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Bearish Evidence

Vidutinės trukmės periodas

Weak Bearish Evidence

Ilgalaikis periodas

Very Strong Bearish Evidence

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Erasca Inc

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.